TCER AB has a total of 28 patent applications. It increased the IP activity by 650.0%. Its first patent ever was published in 2015. It filed its patents most often in United Kingdom, WIPO (World Intellectual Property Organization) and EPO (European Patent Office). Its main competitors in its focus markets pharmaceuticals, biotechnology and measurement are CELCUITY LLC, CHINA INST VETERINARY DRUGS CONTROL and AIRWAY THERAPEUTICS INC.
# | Country | Total Patents | |
---|---|---|---|
#1 | United Kingdom | 5 | |
#2 | WIPO (World Intellectual Property Organization) | 5 | |
#3 | EPO (European Patent Office) | 4 | |
#4 | Canada | 3 | |
#5 | China | 3 | |
#6 | Republic of Korea | 3 | |
#7 | United States | 3 | |
#8 | Australia | 2 |
# | Industry | |
---|---|---|
#1 | Pharmaceuticals | |
#2 | Biotechnology | |
#3 | Measurement |
# | Technology | |
---|---|---|
#1 | Medical preparations | |
#2 | Peptides | |
#3 | Analysing materials | |
#4 | Microorganisms | |
#5 | Therapeutic chemical compounds |
# | Name | Total Patents |
---|---|---|
#1 | Grönlund Hans | 11 |
#2 | Gronlund Hans | 8 |
#3 | Bronge Mattias | 7 |
#4 | Groenlund Hans | 3 |
#5 | Winqvist Ola | 1 |
#6 | Tcer Ab | 1 |
Publication | Filing date | Title |
---|---|---|
GB202010095D0 | Immunotherapy | |
GB201821207D0 | Immunotherapy therapy | |
GB201821205D0 | Immunotherapy | |
KR20200020904A | T-cell proliferation method and use | |
AU2018245014A1 | Multiple sclerosis associated autoantigens, and use thereof in therapy and diagnosis | |
GB201716978D0 | T-cell expansion method and uses | |
GB201710023D0 | T-cell expansion method and uses | |
EP3391047A1 | T-cell reactivity platform | |
EP3182125A1 | T-cell reactivity platform |